Furthermore, a meta-analysis involving 1979 patients, predominantly with breast cancer (99%) receiving anthracycline treatment, demonstrated that elevated MPO levels after treatment were associated with an increased risk of cardiotoxicity [138]. Here, MPO is linked to breast carcinoma.